Coagulation testing of patients with multiple myeloma (median unless otherwise noted).
| Disease status (no.) . | D-dimer, ng/mL . | Fibrinogen, g/L . | AT, U/mL . | Protein C, U/mL . | Protein S, U/mL . | Abnormal APC resistance, % (method) . | FVIII, U/mL . | vWFAg, U/mL . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ND, not done; AT, antithrombin; FVIII, factor VIII activity; VWFAg, von Willebrand factor antigen; ↔, not different than control group; ↑, elevated compared with control group. | |||||||||
| Newly diagnosed (78) | 550 ↑ | 361 ↑ | 0.99 | 1.06 | 0.72 | 24 (aPTT, diluted) | ND | 1.50 ↑ | 49 |
| Newly diagnosed (50) | 456 | ND | 0.99 | 0.96 | 0.98 | 12 (aPTT, 1:5 dilution) | 0.96 | ND | 48 |
| Newly diagnosed (135) | ↔ | ↔ | ↔ | 0.95 | 0.73 | 2 (not stated) | 2.11 ↑ | 1.92 ↑ | 50 |
| Relapsed/refractory+ thalidomide (17) | ND | ND | ↔ | ↔ | ↔ | 0 (aPTT, neat and1:5 dilution) | 3.11 ↑ | 2.93 ↑ | 47 |
| Previously treated (38) | 650 ↑ | 3.5 ↑ | 0.91 | 1.03 | 0.64 | 13 (aPTT diluted) | ND | 1.4 ↑ | 49 |
| Disease status (no.) . | D-dimer, ng/mL . | Fibrinogen, g/L . | AT, U/mL . | Protein C, U/mL . | Protein S, U/mL . | Abnormal APC resistance, % (method) . | FVIII, U/mL . | vWFAg, U/mL . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ND, not done; AT, antithrombin; FVIII, factor VIII activity; VWFAg, von Willebrand factor antigen; ↔, not different than control group; ↑, elevated compared with control group. | |||||||||
| Newly diagnosed (78) | 550 ↑ | 361 ↑ | 0.99 | 1.06 | 0.72 | 24 (aPTT, diluted) | ND | 1.50 ↑ | 49 |
| Newly diagnosed (50) | 456 | ND | 0.99 | 0.96 | 0.98 | 12 (aPTT, 1:5 dilution) | 0.96 | ND | 48 |
| Newly diagnosed (135) | ↔ | ↔ | ↔ | 0.95 | 0.73 | 2 (not stated) | 2.11 ↑ | 1.92 ↑ | 50 |
| Relapsed/refractory+ thalidomide (17) | ND | ND | ↔ | ↔ | ↔ | 0 (aPTT, neat and1:5 dilution) | 3.11 ↑ | 2.93 ↑ | 47 |
| Previously treated (38) | 650 ↑ | 3.5 ↑ | 0.91 | 1.03 | 0.64 | 13 (aPTT diluted) | ND | 1.4 ↑ | 49 |